Human microbiomes in cancer development and therapy

Xia, Chenglai; Su, Juanjuan; Liu, Can; Mai, Zhikai; Yin, Shuanghong; Yang, Chengsheng; Fu, Liwu

doi:10.1002/mco2.221

Cited by 13 publications

(7 citation statements)

References 279 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A tumor is formed by the abnormal proliferation of cells due to the loss of normal regulation of local tissue cells at the gene level under the action of various tumorigenic factors, such as viruses, pollution, tobacco, alcohol, and chemical carcinogens, 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 which is attributed to the action of these factors in stimulating or inactivating key signaling pathways and genes, such as the phosphoinositide 3‐kinase (PI3K)/AKT, Wnt/β‐catenin, Ras/extracellular signal‐regulated kinase (ERK), nuclear factor kappa B (NF‐κB), phospholipase C gamma (PLCγ), sting, signal transducer and activator of transcription (STAT), fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR), c‐Myc, p53, and so on. 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 Among them, the FGF/FGFR pathway plays a significant role in maintaining normal physiological balance of the human body.…”

Section: Introductionmentioning

confidence: 99%

FGFR families: biological functions and therapeutic interventions in tumors

Liu,

Huang,

Yan

et al. 2023

MedComm

View full text Add to dashboard Cite

There are five fibroblast growth factor receptors (FGFRs), namely, FGFR1–FGFR5. When FGFR binds to its ligand, namely, fibroblast growth factor (FGF), it dimerizes and autophosphorylates, thereby activating several key downstream pathways that play an important role in normal physiology, such as the Ras/Raf/mitogen‐activated protein kinase kinase/extracellular signal‐regulated kinase, phosphoinositide 3‐kinase (PI3K)/AKT, phospholipase C gamma/diacylglycerol/protein kinase c, and signal transducer and activator of transcription pathways. Furthermore, as an oncogene, FGFR genetic alterations were found in 7.1% of tumors, and these alterations include gene amplification, gene mutations, gene fusions or rearrangements. Therefore, FGFR amplification, mutations, rearrangements, or fusions are considered as potential biomarkers of FGFR therapeutic response for tyrosine kinase inhibitors (TKIs). However, it is worth noting that with increased use, resistance to TKIs inevitably develops, such as the well‐known gatekeeper mutations. Thus, overcoming the development of drug resistance becomes a serious problem. This review mainly outlines the FGFR family functions, related pathways, and therapeutic agents in tumors with the aim of obtaining better outcomes for cancer patients with FGFR changes. The information provided in this review may provide additional therapeutic ideas for tumor patients with FGFR abnormalities.

show abstract

Section: Introductionmentioning

confidence: 99%

FGFR families: biological functions and therapeutic interventions in tumors

Liu,

Huang,

Yan

et al. 2023

MedComm

View full text Add to dashboard Cite

show abstract

“…The microbiota plays an important role in human health and diseases (Xia et al, 2023;Xiang et al, 2023). In recent years, Organs and tissues traditionally regarded as sterile have been found to contain different microbial populations, and these microbial populations play a vital role (Xue et al, 2023).…”

Section: Discussionmentioning

confidence: 99%

Identification of a brand intratumor microbiome signature for predicting prognosis of hepatocellular carcinoma

Song

Xiang

Zhou

et al. 2023

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

PurposeGiven that prognosis of hepatocellular carcinoma (HCC) differs dramatically, it is imperative to uncover effective and available prognostic biomarker(s). The intratumor microbiome plays a signi cant role in the response to tumor microenvironment, we aimed to identify an intratumor microbiome signature for predicting the prognosis of HCC patients accurately and investigate its possible mechanisms subsequently. MethodsThe TCGA HCC microbiome data (TCGA-LIHC-microbiome) was downloaded from cBioPortal. To create an intratumor microbiome related prognostic signature, univariate and multivariate Cox regression analyses were used to quantify the association of microbial abundance and patients' overall survival (OS), as well as their diseases speci c survival (DSS). The performance of the scoring model was evaluated by the area under the ROC curve (AUC). Based on the microbiome related signature, clinical factors, and multi-omics molecular subtypes on the basis of "icluster" algorithm, nomograms were established to predict OS and DSS. Patients were further clustered into three subtypes based on their microbiome related characteristics by consensus clustering. Moreover, deconvolution algorithm, weighted correlation network analysis (WGCNA) and gene set variation analysis (GSVA) were used to investigate the potential mechanisms. ResultsIn TCGA LIHC microbiome data, the abundances of 166 genera among the total 1406 genera were considerably associated with HCC patients' OS. From that ltered dataset we identi ed a 27-microbe prognostic signature and developed a microbiome related score (MRS) model. Compared with those in relatively low risk group, patients in higher risk group own a much worse OS(P < 0.0001). Besides, the time-dependent ROC curves with MRS showed excellent predictive e cacy both in OS and DSS. Moreover, MRS is an independent prognostic factor for OS and DSS over clinical factors and multi-omics based molecular subtypes. The integration of MRS into nomograms signi cantly improved the e cacy of prognosis prediction (1 year AUC:0.849, 3 year AUC: 0.825, 5-year AUC: 0.822). The analysis of microbiome-based subtypes on their immune characteristics and speci c gene modules inferred that intratumor microbiome may affect the HCC patients' prognosis via modulating the cancer stemness and immune response. ConclusionMRS, a 27 intratumor microbiome related prognostic model, was successfully established to predict HCC patients overall survive independently. And the possible underlying mechanisms were also investigated to provide a potential intervention strategy.

show abstract

“…This configuration gives rise to a multifaceted microecological environment. In the physiological state of the human body, a profusion of microorganisms congregates, culminating in the creation of a complex microecological milieu ( Xia et al, 2023 ). Oral microbiota comprises a consortium of microorganisms specifically adapted to inhabit the human mouth.…”

Section: Introductionmentioning

confidence: 99%

Insights into the oral microbiota in human systemic cancers

Su,

Yang,

Sheng

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

The oral cavity stands as one of the pivotal interfaces facilitating the intricate interaction between the human body and the external environment. The impact of diverse oral microorganisms on the emergence and progression of various systemic cancers, typified by oral cancer, has garnered increasing attention. The potential pathogenicity of oral bacteria, notably the anaerobic Porphyromonas gingivalis and Fusobacterium nucleatum, has been extensively studied and exhibits obvious correlation with different carcinoma types. Furthermore, oral fungi and viruses are closely linked to oropharyngeal carcinoma. Multiple potential mechanisms of oral microbiota-induced carcinogenesis have been investigated, including heightened inflammatory responses, suppression of the host immune system, influence on the tumor microenvironment, anti-apoptotic activity, and promotion of malignant transformation. The disturbance of microbial equilibrium and the migration of oral microbiota play a pivotal role in facilitating oncogenic functions. This review aims to comprehensively outline the pathogenic mechanisms by which oral microbiota participate in carcinogenesis. Additionally, this review delves into their potential applications in cancer prevention, screening, and treatment. It proves to be a valuable resource for researchers investigating the intricate connection between oral microbiota and systemic cancers.

show abstract

Human microbiomes in cancer development and therapy

Cited by 13 publications

References 279 publications

FGFR families: biological functions and therapeutic interventions in tumors

FGFR families: biological functions and therapeutic interventions in tumors

Identification of a brand intratumor microbiome signature for predicting prognosis of hepatocellular carcinoma

Insights into the oral microbiota in human systemic cancers

Contact Info

Product

Resources

About